Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

etoposide

View Patient Information
A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum. Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:demethyl epipodophyllotoxin ethylidine glucoside
Foreign brand name:Lastet
Abbreviation:EPEG
Code name:VP 16
VP 16213
VP-16
VP-16-213
VP16
Chemical structure:4'-demethylepipodophyllotoxin 9-[4,6-O-ethylidene-beta-D-glucopyranoside]
9-[(4,6-O-ethylidene-beta-D-glucopyranosyl]oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search